详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

HMGN5 expression in bladder cancer tissue and its role on prognosis.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chendu, Sichuan Province, P.R. China

出处：

DOI：

ISSN：

关键词： HMGN5 Bladder cancer Urothelial cancer Clinical stage Pathological type Prognosis

摘要：

High mobility group protein N5 subtype (HMGN5) is overexpressed in bladder cancer tissue, while its specific mechanism in bladder cancer oncogenesis has not been fully elucidated. This study intends to investigate the impact of HMGN5 on clinical staging and prognosis of bladder cancer. A total of 26 cases of patients with bladder transitional cell carcinoma (BTCC) received transurethral resection (TUR-BT) in our hospital between March 2015 and February 2016. Para-carcinoma tissue at 5 cm away from cancer tissue was selected as normal control. The expressions of HMGN5 mRNA and protein in different clinical stages were tested by Real-time PCR and Western blot. The relationship between HMGN5 expression and clinical stage along with prognosis was analyzed. HMGN5 mRNA was significantly elevated in BTCC tissue compared with that in para-carcinoma tissue (p < 0.05). HMGN5 mRNA level was gradually upregulated following BTCC upstage according to UICC-TNM stage and WHO stage. The level of HMGN5 protein showed similar changes with mRNA. Follow-up results demonstrated that patients with high HMGN5 level have more tendency of occurrence. HMGN5 protein level has an important influence on BTCC clinicopathological staging and prognosis. This investigation provides theoretical basis the future therapy of bladder cancer.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2018]版：

大类 | 4 区医学

小类 | 4 区药学

最新[2023]版：

大类 | 4 区医学

小类 | 4 区药学

第一作者：

第一作者机构： [1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chendu, Sichuan Province, P.R. China

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]The Clinical Implications and Molecular Mechanism of CX3CL1 Expression in Urothelial Bladder Cancer. [2]An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer [3]PD-L1 expression and its correlation with tumor biomarkers in Chinese urothelial bladder cancer [4]Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation [5]膀胱移行细胞癌患者尿脱落细胞中MUC7和CK20的表达及其临床意义 [6]Overexpression of PTK6 predicts poor prognosis in bladder cancer patients [7]Potential molecular biomarkers for the diagnosis and prognosis of bladder cancer [8]Controlling Nutritional Status Score Before Receiving Treatment as a Prognostic Indicator for Patients With Urothelial Cancer: An Exploration Evaluation Methods [9]Efficiency of transurethral en-bloc resection vs. conventional transurethral resection for non-muscle-invasive bladder cancer: An umbrella review [10]RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03)